SAN ANTONIO — In this video, Timothy Wilens, PhD, chief of the division of child and adolescent psychiatry and co-director of the Center for Addiction Medicine at Massachusetts General Hospital, provides an update on ADHD medications.
Wilens discusses recent developments in FDA-approved products, such as combination pharmacotherapies and stimulants as well as advancements in the pipeline and medications effective for niche populations.
“We’re appreciating more and more that ADHD needs to be treated across the lifespan,” Wilens said. “We have new agents that have just been FDA-approved and add to the repertoire of available agents and new pipeline medications that one should stay tuned for the next generation of ADHD treatment.”
Disclosure: Wilens reports receiving grant support from the NIH (NIDA); serving as a consultant for: Euthymics/Neurovance, NIH (NIDA), Ironshore, Sunovion, TRIS; U.S. National Football League (ERM Associates), U.S. Minor/Major League Baseball; Bay Cove Human Services and Phoenix House (Clinical Services); publishing a book, Straight Talk About Psychiatric Medications for Kids (Guilford Press) and co-editing books ADHD in Children and Adults (Cambridge Press) and Massachusetts General Hospital Comprehensive Clinical Psychiatry (Elsevier); co-owning a copyrighted diagnostic questionnaire, Before School Functioning Questionnaire; and holding a licensing agreement with Ironshore (BSFQ Questionnaire).